Human beta IG-H3 Antibody

Catalog #: MAB2935
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB2935
MAB2935-SP

All beta IG-H3 Antibodies

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human beta IG-H3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human beta IG-H3 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant mouse beta IG-H3.

Source

Monoclonal Mouse IgG₁ Clone # 348506

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human beta IG-H3
Gly24-His683
Accession # Q15582

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human beta IG-H3 (Catalog # 3409-BG)

Human beta IG-H3 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human beta IG‑H3 Biotinylated Antibody (Catalog # BAF2935)

Standard: Recombinant Human beta IG-H3 Protein, CF (Catalog # 3409-BG)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: beta IG-H3

Beta IG-H3, also known as TGFBI and RGD-CAP, is a matricellular adaptor protein that is induced in most cell types in response to TGF-beta stimulation (1-4). The human beta IG-H3 cDNA encodes a 683 amino acid (aa) precursor that includes a 23 aa signal sequence, one EMI domain, four FAS1 domains, and one RGD motif (1). Human beta IG-H3 shares 91% and 93% aa sequence identity with mouse and porcine beta IG-H3, respectively. beta IG-H3 is expressed as a 75 kDa protein with no post-translational additions (5). Following secretion, cleavages at multiple positions near the C-terminal end liberate peptides with pro-apoptotic activity (5,6). Peptides that encompass the RGD motif contribute to the pro-apoptotic effects of TGF-beta (6). FAS1 domains contain YH motifs that are characterized by conserved Tyr and His residues (7). The YH motifs in each of the FAS1 domains enable beta IG-H3 binding to matrix Fibronectin, Collagen I, and Collagen VI (3, 8 - 10) in addition to cell expressed Integrins alpha _V beta ₃, alpha _V beta ₅, and alpha ₃ beta ₁ (7, 8, 11, 12). The expression of beta IG-H3 is modulated at particular developmental stages in some cell types. It is upregulated in keratinocytes and immature dendritic cells but downregulated in osteoblasts (8, 11, 13). It promotes keratinocyte differentiation but blocks osteoblast differentiation (8,11). beta IG-H3 stimulates macrophage endocytosis and vascular endothelial cell proliferation and migration (12, 13). High glucose levels induce beta IG-H3 in renal proximal tubule cells which is predictive of diabetic nephropathy (3). Several point mutations (clustered in the fourth FAS1 domain) of beta IG-H3 are linked to different corneal dystrophies (14). beta IG-H3 is downregulated in many cancers (4, 15) and functions as a suppressor of tumorigenicity when overexpressed (2, 4, 15).

References

Skonier, J. et al. (1992) DNA Cell Biol. 11:511.
Skonier, J. et al. (1994) DNA Cell Biol. 13:571.
Lee, S-H. et al. (2003) Kidney Int. 64:1012.
Zhao, Y.L. et al. (2002) Oncogene 21:7471.
Andersen, R.B. et al. (2004) Biochemistry 43:16374.
Kim, J-E. et al. (2003) Oncogene 22:2045.
Kim, J-E. et al. (2002) J. Biol. Chem. 277:46159.
Thapa, N. et al. (2005) Bone 36:232.
Hanssen, E. et al. (2003) J. Biol. Chem. 278:24334.
Billings, P.C. et al. (2002) J. Biol. Chem. 277:28003.
Oh, J-E. et al. (2005) J. Biol. Chem. 280:21629.
Nam, J-O. et al. (2003) J. Biol. Chem. 278:25902.
Cao, W, et al. (2006) Blood 107:2777.
Stewart, H.S. et al. (1999) Hum. Mutat. 14:126.
Zhao, Y. et al. (2006) Mol. Carcinog. 45:84.

Long Name

TGF-beta Induced Gene H3

Entrez Gene IDs

7045 (Human); 21810 (Mouse)

Alternate Names

beta IGH3; beta IG-H3; BIGH3EBMD; CDB1; CDG2; CDGG1transforming growth factor, beta-induced, 68kD; CSD; CSD1; CSD2; CSD3; Kerato-epithelin; LCD1; RGD-CAP; RGD-containing collagen-associated protein; TGFBI; TGFBIP; transforming growth factor, beta-induced, 68kDa; transforming growth factor-beta-induced protein ig-h3

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citation for Human beta IG-H3 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1

Inhibition of human scleral fibroblast cell attachment to collagen type I by TGFBIp.
Authors: Shelton L, Rada JA
Invest. Ophthalmol. Vis. Sci., 2009-04-22;50(8):3542-52.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: ICC, Neutralization, Western Blot